Ranibizumab could cause GA progression in CNV

Ranibizumab injections could cause geographic atrophy (GA) progression in eyes with choroidal neovascularisation (CNV).

Ranibizumab injections could cause geographic atrophy (GA) progression in eyes with choroidal neovascularisation (CNV).

Dr Giuseppe Querques et al., Department of Ophthalmology, University Paris Est Creteil, Centre Hospitalier Intercommunal de Creteil, Paris, France, conducted a retrospective, interventional, consecutive case series on the charts of 21 eyes of 21 consecutive patients with GA caused by age-related macular degeneration (AMD). All patients were administered intravitreal ranibizumab injections for CNV at a minimum of 24 months earlier.

Best-corrected visual acuity (BCVA) significantly worsened at the 24-month follow-up visit and a significant increase of GA area was presented. However, there was a significant reduction in intraretinal cystic lesions, subretinal fluid and pigment epithelium detachment.

To read the abstract please visit the British Journal of Ophthalmology.

Related Videos
Fluid dynamics in wet macular degeneration: How fluid type affects visual acuity
EURETINA leadership discusses what to expect at the 2022 Congress, outlines Women in Retina programme
Paediatric eyes repair better with scleral buckling, adults need vitrectomy only for giant retinal tear-related detachments
Clinical trials in wet AMD: Impact of central subfield thickness, volatility on visual acuity
Post hoc analysis of Copernicus, Galileo trials find time since diagnosis affects BCVA outcomes in CRVO
Related Content
© 2023 MJH Life Sciences

All rights reserved.